The 156 patients matches almost exactly the enrollment change on the clinicaltrials.gov website (1322 to 1476). I had picked the points of the released enrollment curve, so 156 translates to randomized patients that had the 8 shots of primary therapy plus 2 maintenance doses. Alternatively, 156 patients with about 6 months of treatment would correspond to replacements for the Stimuvax arm only. The latter is the speculation that I read on yahoo, which I think we both considered the FDA unlikely to have approved of.